Has Natasha Sra, MD received payments from drug or device companies?

Yes. Drug and device makers reported $760 in general payments to Natasha Sra, MD across 32 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Natasha Sra, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Natasha Sra, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Natasha Sra, MD

Psychiatry · Little Rock, ARNPI 1194353607

Payments from drug & device makers

$760in general payments, 2019–2025

Across 32 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$237
Otsuka America Pharmaceutical, Inc.$140
Teva Pharmaceuticals USA, Inc.$139
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49
Collegium Pharmaceutical, Inc.$45
Acadia Pharmaceuticals Inc$44
plus $106 from 4 others

What the payments were for

Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	11	$237
Otsuka America Pharmaceutical, Inc.	6	$140
Teva Pharmaceuticals USA, Inc.	4	$139
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$49
Collegium Pharmaceutical, Inc.	2	$45
Acadia Pharmaceuticals Inc	2	$44
Alkermes, Inc.	2	$43
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$29
Johnson & Johnson	1	$19
Vanda Pharmaceuticals Inc.	1	$15

How this compares

$760 in reported general payments places this provider in the 60th percentile of 235 psychiatry providers in Arkansas.

See all psychiatry providers in Arkansas →

Medicare billing

Part B allowed, 2024

$7,089

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Nortriptyline Hcl	16	$186
Duloxetine Hcl	13	$185
Buspirone Hcl	22	$180
Haloperidol	11	$162
Trazodone Hcl	34	$109
Fluoxetine Hcl	14	$64

Paid to pharmacies, not to this prescriber.

Other psychiatry in Little Rock

Leslie SmithLittle Rock$7.9M
Gintaras AukstuolisLittle Rock$6.6M
Paul WylieLittle Rock$3.4M
Tad TillemansLittle Rock$656K
Renea HendersonLittle Rock$366K
Margaret WeissLittle Rock$29K
Duong NguyenLittle Rock$14K
Bradley DinerLittle Rock$8K
Philip MizellLittle Rock$5K
Richard FlaniginLittle Rock$5K

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →